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Summary Recombinant interleukin-2 (rIL-2) was used to treat 31 patients with progressing metastatic
malignant melanoma. Only three patients had disease confined to non-visceral sites; the median number of
organ sites involved was four. The first dose of rIL-2 was given intrasplenically (to stimulate cytotoxic cells in
high concentration) via a femoral artery catheter, and four further i.v. doses were given over 6 days. A total of
three courses at 21-day intervals was planned. Doses were escalated in 15 patients from I x 106 to 16.4 x 106
Cetus units m-2. The maximum tolerated dose (11.0 x 106 U m-2) was used in the other 16 patients. Of the 71
courses, severe but transient toxicity requiring interrruption of rIL-2 or additional care occurred on three
courses (dyspnoea) and 15 from hypotension, but the patients' performance status improved. Four patients
had partial tumour responses although in only one patient did response occur in all sites of disease. However,
responses occurred in visceral sites and six patients are alive at 9-16 months. IL-2 is of use in advanced
melanoma and does not need complicated ICU facilities.
Interleukin-2 (rIL-2), a 15,000 Da glycoprotein, is the prin-
cipal component of the T-cell growth factor (Morgan et al.
1976). Incubation of human peripheral blood lymphocytes
with rIL-2 has generated lymphoid cells capable of lysing
fresh, natural killer cell resistant tumour cells but not normal
cells. These functionally defined lymphokine activated killer
(LAK) cells are therefore capable of distinguishing between
freshly isolated human (and murine) tumour cells and normal
cells (Grimm et al., 1982). The development of DNA cloning
technology led to wider availability of recombinant IL-2 and
clinical study began in patients with a variety of cancers. The
early clinical results have been summarised recently by
Rosenberg et al. (1987). Patients with advanced cancer in
whom standard therapy had failed or for whom no standard
therapy was available were treated with high-dose rIL-2
alone or in combination with LAK cells. The LAK cells were
obtained from the cancer patients by repeated leucophereses,
incubation of the cells with rIL-2 in vitro and then reinfusion
of the cultured cells. Tumour shrinkage and in some cases
complete response were noted in these advanced patients
treated with rIL-2 and LAK cells and also with high-dose
rIL-2 alone, but such treatment, even with the rIL-2 alone,
was associated with serious side-effects (Rosenberg et al.,
1987), Respiratory distress occurred in 11 of 53 courses of
high-dose rIL-2, requiring intubation in six, hypotension
requiring pressor agents occurred in 34 of 53 courses and
there were three treatment deaths. Other side-effects included
oliguria, thrombocytopenia and anaemia. However, in
16patients treated for advanced melanoma with the high-
dose rIL-2 there were five partial remissions.
The median survival of patients with metastic melanoma is
only 6 months and 3 months for patients with visceral metas-
tases or multiple metastatic sites, despite chemotherapy with
the most active agents (Balch et al., 1985; Mastrangelo et al.,
1985; Thatcher et al., 1986). High-dose chemotherapy with
marrow rescue also has been used but again there has been
little impact on survival and tumour response has been
achieved only with considerable toxicity (Cornbleet et al.,
1983; Thatcher et al., 1989). New approaches to treatment of
advanced melanoma are therefore urgently needed, partic-
ularly as the tumour is rapidly increasing in incidence. The
technique of multiple leucophereses and culture with rIL-2 to
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obtain LAK cells with subsequent reinfusion is cumbersome
and not readily applicable. The considerable toxicity
associated with the use of high-dose rIL-2 is also a serious
obstacle.
In an attempt to avoid the logistic difficulties in obtaining
LAK cells and the serious side-effects of high-dose rIL-2, a
novel method of rIL-2 administration was designed. The
spleen is rich in LAK cell precursors (Ettinghausen et al.,
1985) and intrasplenic administration of rIL-2 might be
expected to stimulate a population present at high concentra-
tion in the organ. Further doses of rIL-2 given as 1 h
infusions (rather than in 15 min and three times daily as in
Rosenberg's technique) were given on alternate days in an
attempt to diminish the side-effects while maintaining
antitumour activity.
Materials and methods
Patient population
Thirty-one patients with metastatic, progressing melanoma
were entered into the study which commenced in December
1986 and was completed 12 months later. All patients had
clinically evaluable disease and none had received antitumour
treatment for at least 4 weeks before study entry. Five
patients had received previous chemotherapy with a Dacar-
bazine combination regimen and six patients previous
radiotherapy. All patients had to have a Karnofsky score
>50, be without major cardiovascular, respiratory system
diseases and have no obvious CNS metastases (although
routine CT brain scans were not performed).
Pre-treatment investigations included patient history,
clinical examination, routine haematology, biochemical
profiles and plain radiography. Isotope or other scans were
performed as necessary to measure and evaluate disease. A
series of immunological investigations were also undertaken
on peripheral blood cells and are the subject of another
report (Ghosh et al., 1989). There were 18 male and
13 female patients with a median age of49 years with a range
of 22-69 years. The pattern of metastases of the 31 patients
is shown in Tables I and II. Fifteen patients with 62 meta-
static sites (median four organ sites involved) entered a phase
I escalating dose study. Only two of these patients had solely
non-visceral disease, i.e. limited to peripheral lymph nodes,
skin and superficial soft tissues. The other 16 patients with 45
metastatic sites (median three organ sites involved) entered
the phase II study with only one patient having non-visceral
metastases.
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Table I Patient details, phase I study
Dose x 10i Um-2 Overall Duration of
Metastatic Body surface course response stable disease Survival
Pat. no. Age Sex sites area (mi) 1 2 3 w. course no. or response Status (months)
1 60 M D,N1,2,3,0,P,S 1.8 1.0 2.0 - P D 2
2 59 M D,H,N1,2,3,P,S 1.9 1.0 - - P1 D 2
3 49 F D,H,N2,P 1.6 2.0 3.4 5.0 P D 4
4 39 F D,N24,S 1.7 2.0 3.4 5.0 S 14 D 16
5 66 M N3,P,S 1.9 3.4 5.0 7.0 PR(2) 6 D 8
6 47 M NI,2,0,P,S 1.8 3.4 5.0 7.0 P2 D 11
7 63 M D,N1,2,O,S 1.6 5.0 7.0 9.3 S 5 D 8
8 58 M N1,3,4,S 1.8 5.0 7.0 - P D 7
9 65 M N4,O 1.7 7.0 9.3 12.4 S 8 D 10
10 31 F D,N1,S 1.7 7.0 9.3 12.4 PR(3) 16 A 16
11 45 M D,H,N3,S 1.8 9.3 12.4 - P D 2
12 50 F H,O 1.6 9.3 12.4 16.5 S 3 D 4
13 33 F H,M,N, 1.7 12.4 - - P D 1
14 40 M D,N1,2,O,P,S 1.8 12.4 - - P D 1
15 53 M D,S 2.0 12.4 12.4 - S 4 A 11
Sites: D, skin; H, liver; M, marrow; N, nodes; 1, regional; 2, peripheral (not 1); 3, mediastinal; 4, intra-abdominal; 0, bone; P, pulmonary; S, soft
tissue.
Overall response: P, progression (P', pulmonary metastases responded; P2, skin metastases responded); PR, partial response, ( ) indicates course
number that response was noted; S, stable; A, alive; D, dead.
Table II Patient details, phase 11(11.0 x 106 Um-2) study
Overall Duration of
Metastatic Body surface No. of response stable disease Survival
Pat. no. Age Sex sites area (m2) courses given w. course no. or response Status (months)
16 45 F H 1.7 3 S 16 A 16
17 52 M N1,2,3,P,S 1.6 2 P D 6
18 42 M O,P;S,SI 1.9 3 PR(1) 4 A 11
19 56 M A,N2,P,SP,S 1.9 1 P D 2
20 52 F D,O,P 1.5 1 P D 2
21 36 F 0 1.5 3 S 10 A 10
22 44 M N3 2.0 3 P D 7
23 63 F D,O 1.7 3 S 5 D 8
24 22 F D,H,P 1.6 1 P D 2
25 43 M N3,O,P 1.9 2 P D 4
26 63 F D,H,P 1.7 1 P D 1
27 69 F D,N,,O,P 1.6 3 P D 8
28 30 M D,N4,0,P 1.5 2 P D 5
29 55 M D,P 1.6 2 P D 6
30 40 M D,S 1.9 3 PR(3) 3 A 9
31 58 F D,P 1.8 3 P D 5
See notes to Table 1.
A, adrenal; SI, small intestine; SP, spleen.
Patient nos. 3, 8, 18, 19, 22, 25, 28, 29 and 31 received chemotherapy on progression, with static disease in 8, 18, 28 and 29.
Interleukin-2
The rIL-2 used in the study was kindly supplied by the Cetus
Corporation (Emeryville, California). Specific activity was
3 x 106 Cetus unit (U) per mg of protein and reconstitution
was with sterile water followed by infusion in 5% detrose
over I h.
The first dose of rIL-2 was infused by a syringe pump via a
catheter positioned in the splenic artery. A femoral Seldinger
approach using the Simmon's no. 1 cerebral catheter (Wil-
liam Cook, Denmark) for the catheterisation was employed.
Contrast injection confirmed satisfactory position both
before and after the rIL-2 infusion. After the 1-h infusion the
catheter was removed under screen control. Further doses of
rIL-2 were given intravenously via a peripheral vein over 1 h
(controlled by a volumetric pump). The first intravenous dose
was given 4 h after the intrasplenic dose and further i.v.
doses at 48, 96 and 144 h, i.e. on alternate days. A complete
treatment course therefore involved five rIL-2 administra-
tions given over a 6-day period. Treatment was repeated to a
maximum of three courses at 21-day intervals from the start
of the rIL-2.
In the phase I study, 35 courses were given in 15 patients.
Doses were escalated according to a modified Fibonacci
scheme from 1 x 106 to 16.4 x 106 U m-2. Doses were
escalated after two patients had been entered at each dose
level and also 'within' patients who had successfully com-
pleted treatment at the lower dose. Escalation continued
providing no grade III or IV toxicity occurred as assessed by
standard World Health Organization criteria. The rIL-2 was
discontinued if grade III or IV toxicity occurred during a
course. Any patient with grade IV toxicity did not receive
further rIL-2 but patients with grade III toxicity continued
on the treatment programme providing that the toxicity com-
pletely resolved or returned to grade I levels.
Supportive care
Patients received paracetamol every 6 h when required for
pyrexia. No other routine supportive medication was used.
Moderate to severe hypotension was treated conservatively or
with an infusion of 500 cm3 ofnormal saline over 30-40 min.
On four occasions only hydrocortisone 100mg i.v. as one
dose was also given in three patients with marked hypo-
tension. No pressor agents were used. No specialised
monitoring was undertaken and patients were nursed on a
general medical oncology ward. Regular records of the
patients' general status, blood pressure, pulse and
temperature were taken every 15 min (x 8) after rIL-2, then
every 30 min (x 4), hourly (x 4), and thereafter 4 hourly,
while on treatment.
Following relapse or progression chemotherapy with DTIC
250mgm2 daily for 5 days and melphalan 15mgm2 i.v.
bolus day 3 was considered with other appropriate therapy as
indicated.772 N. THATCHER et al.
Response, toxicity evaluation andfollow-up
Standard WHO criteria were used to define objective res-
ponse and toxicity (Miller et al., 1981). The worst toxicity
grade experienced during an rIL-2 course was recorded. In
addition the time of onset and duration of side-effects were
recorded. Full blood counts and routine biochemistry were
performed at the time of rIL-2 administration and weekly
(x 2) between courses. The patients' performance scores
(Miller et al., 1981) were also assessed, immediately before
rIL-2 and a month after the last course.
A complete response (CR) was to be recorded if all
evidence of melanoma disappeared for at least 4 weeks.
Partial response (PR) was defined as a decrease by at least
50% in the sum of the product of the longest perpendicular
diameters of measured lesions for at least 4 weeks. Stable
disease (SD) was recorded in the presence of tumour which
did not qualify for partial response or disease progression.
Progressive disease (PD) was defined as a 25% or greater
increase in the sum of the product of the perpendicular
diameters of measurable disease or the appearance of new
lesions. Patients were evaluated for response 4 weeks after
completion of therapy. In the presence of progressive disease
rIL-2 treatment was discontinued. Subsequent evaluation
occurred at 4-6-weekly intervals for 6 months and 2-3-
monthly therafter.
Results
Phase I study
In the escalating dose, phase I study 15 patients received a
total of 35 (of a possible 45) rIL-2 courses (see Table I).
Eight patients received all three courses. The median single
dose was 7.0 x 106 U m-2 giving a median dose per course of
35 x 106U m-2 with a range of 5-82.5. The median
cumulative dose was 106 x 106 Um-2 (range 5-191). No
grade IV, life threatening toxicity occurred (see Table III).
There were no dosage reductions or delays due to toxicity
but 11 individual doses out of a possible 175 were omitted
due to toxicity. One patient with hepatic and marrow meta-
stases had grade 3 anaemia, thrombocytopenia and elevation
of bilirubin. Mild transient elevations of bilirubin up to three
times normal occurred on five other courses. Transient eleva-
tions of aspartate aminotransferase (AST) were more fre-
quent, occurring on 14 courses with elevations of 1.26-4
times the upper limit of normal. No oliguria or marked renal
impairment occurred. Gastrointestinal toxicity was only of
moderate severity when experienced and responded to
routine care but regular antiemetics were needed on two
courses. The median onset of gastrointestinal toxicity was 2 h
(range 1-6 h) after rIL-2 with a median duration of 3 h
(range 1-20 h). Fever, median 39.2°C, range 37.6-40.6°C
occurred on all courses except two and most patients felt
chilled. Patients were symptomatic from the fever for 1-4 h
(median 3 h) following rIL-2. No peripheral neurotoxicity
was noted but some patients felt more than usually lethargic
up to 3 h after treatment. Two patients gained weight
(> 10% to < 15% of the pretreatment body weight). In one
patient this was associated with pre-existing ascites.
There were three episodes of a dry, itchy desquamating
rash lasting 2-4 days and three episodes of arthralgia and
myalgia lasting up to 12 h. There was marked eosinophilia
(>20% of the total WBC) on 12 courses, but this was
without apparent relation to rashes, arthralgia or myalgia.
An autoantibody screen was routinely performed and, on
four occasions only, antibodies to rheumatoid factor and
cardiolipin were newly detected. No autoantibodies to
thyroid, stomach, smooth muscle, etc., were detected. One
patient shortly after splenic artery catheterisation developed
symptoms and signs of a peripheral vessel embolism in the
foot but there was rapid recovery following conservative
management.
The most clinically relevant toxicity concerned dyspnoea
and hypotension. There were two episodes of dyspnoea at
rest requiring bronchodilator therapy and nine episodes of
severe hypotension. The median onset of these side-effects
was 2 h (range 1-8 h) after rIL-2, lasting for only 30 min to
2 h. The duration of any degree of dyspnoea or hypotension
was longer: median 4 h (range 1-11 h). Five of the nine
episodes of hypotension occurred with the 26 courses in
which the rIL-2 dose was lower than 12.4 x 106 U m-2. The
remaining four episodes of severe hypotension and the two
episodes of severe dyspnoea occurred during the nine courses
when the rIL-2 dosage was 12.4 x 106 U m-2 or higher.
Phase II study
On the basis of the previous dose ranging study,
11 X 106 U m-2 was chosen as the maximum tolerable dose
and used in the phase II evaluation. Thirty-six courses of a
possible 48 were given with 19 individual doses omitted
because of toxicity. The median cumulative dose was
140 x 106 U m-2 (range 11- 165). One patient with massive
intra-abdominal disease including bilateral adrenal metas-
tases developed temporary respiratory arrest following
removal of the splenic catheter. No other grade IV toxicity
occurred. The other main toxicities in the phase II study are
shown in Table III. On four occasions anaemia (6.5-9.4 g%)
occurred and on one occasion transfusion was required.
Again transient elevations in AST and creatinine occurred on
13 courses with increases from 1.26 to less than 3-fold the
upper limit of normal.
Although vomiting occurred on 17 courses it was transient
and only two courses required regular antiemetics. The
median onset of gastrointestinal toxicity was 2 h (range
1-5 h) with a median duration of 3 h (range 1- 13 h). Diarr-
hoea and central nervous system side-effects were uncommon
and only mild. Again, fever occurred on the majority of
courses and on 18 courses was in excess of 40°C but the
median maximum temperature was 39.2°C (range 37.4-40.3).
The accompanying chills were only temporary, lasting for
0.5-3 h (median 2 h) after giving the rIL-2. With the first
course of rIL-2 one patient had transient 'splenic' pain fol-
lowing the catheterisation. A desquamating rash occurred
after three courses, lasting up to 48 h. On 22 courses there
was some arthralgia and/or myalgia with a median onset of
3 h after the rIL-2 (range 1-8 h) lasting for a median of 3 h
(range 1-24 h). Autoantibodies were not detected.
Eosinophilia greter than 20% of the total white count occur-
red on 21 courses.
There were five episodes of severe hypotension other than
the patient who had a transient respiratory arrest. This
patient accounted for the sole episode of grade 4, pulmonary
Table III Toxicity
Number ofcourses with WHO grades
Phase I (35) Phase II (36)
Grade 0 1 2 3 0 1 2 3
Haemoglobin 12 15 6 2 29 3 3 1
Leucocytes 33 1 1 - 34 1 1
Platelets 33 1 - 1 35 1
Bilirubin 29 3 2 1 32 4 -
AST 21 9 5 - 26 7 3 -
Creatinine 33 2 - - 33 2 1
Nausea/vomiting 12 5 16 2 4 15 15 2
Diarrhoea 30 4 1 - 31 4 1
Fever 2 4 24 5 2 8 8 18
CNS 25 7 3 - 31 5 - -
Pulmonary 31 - 2 2 31 2 2 1
(grade 4)
Hypotensiona 16 3 7 9 18 8 4 6
(with one
grade 4)
aHypotension grades: 1, > 20 mmHg systolic change or light
headedness; 2, > 30 mmHg systolic change or orthostatic symptoms
with pulse increase > 15 with upright posture; 3, >40 mmHg systolic
change or require fluid therapy.INTERLEUKIN-2 AND METASTATIC MELANOMA 773
toxicity and hypotension. Three other patients had an in-
crease in blood pressure of between 10 and 20 mmHg. These
side-effects were transient, again with a median onset of 3 h
following rIL-2 (range 2-7 h) and a median duration of 5 h
(range 2-13 h), for any degree of hypotension or dyspnoea.
Response
Four patients had a partial response but in only one of these
did response occur in all metastatic sites. In the other three
patients, partial response in one or more metastatic sites was
associated with stable disease in other sites. The course
number and rIL2 dose associated with the response were
inconsistent. Durations of static disease and response are also
given in Tables I and II. Another 19 patients had progressive
disease and the remaining patients stable disease. Sites of
response included skin (two patients), soft tissue (two
patients), peripheral lymph nodes (one patient), mediastinum
(one patient), parenchymal lung (one patient) and one patient
each in liver and small bowel metastases (see Tables I and
II). Nine patients received chemotherapy on progression (see
Table II). There was no clear difference between the lympho-
cyte count during rIL-2 for patients whose disease progressed
and those patients without progression (Figure 1). Median
values and ranges of the lymphocyte count are displayed in
Table IV. In some patients the performance score improved
despite the advanced stage of disease in the patient popula-
tion (Table V). The median survival of the whole group of
31 patients was 8 months with a range of 1-16 months. Six
patients remain alive with stable disease.
a)
a,7
C-
0 a)E
E
-J
Figure 1 Lymphocyte count during IL-2 treatment. Continuous
line, non-progression; dotted line, progression.
Table IV Lymphocyte count (cells x 106 1-')
Non-progressors Progressors
Day Median Range Day Median Range
0 1776 742-3150 0 1840 490- 7769
2 819 165-5394 2 833 77-4950
7 1322 510-5804 7 1989 605-3096
14 2505 364-4958 14 4127 7000-5880
21 2035 350-9333 21 2557 700-4218
23 1150 158- 805 23 1260 371-7130
28 2156 1067-6594 28 1677 689-3213
35 3862 1804-6375 35 4125 1007-9730
42 2332 1416-7788 42 2382 869-4234
44 3939 1860-6195 44 4224 2220-5538
49 2584 936-3850 49 2160 1292-3105
56 3914 456-6030 56 3183 1474-4758
63 2185 1660-8418 63 2222 1056-5382
Table V Change in performance status with rIL-2
Phase I Phase II
One month One month
Pre rIL-2 after last rIL-2 Pre rIL-2 after last rIL-2
PS 0 - 2 - 2
1 6 3 8 3
2 8 3 6 5
3,4a 1 7(5) 2 6(4)
aIncludes patients dying, number in parentheses, within 1 month of
last course rIL-2.
PS: 0, normal activity; 1, ambulatory, candolightwork; 2, ambulatory,
selfcaring,unabletodoanywork; 3,limitedselfcare,confinedtobedor
chair; 4, completely disabled, no selfcare. See Miller et al. (1981).
Discussion
Interleukin-2 was recognised as a T cell growth factor by
Morgan et al. in 1976. It was also noted later to be a
differentiation factor for cytotoxic T cells and was found to
activate natural killer cells and LAK cells (Grimm et al.,
1982). Adoptive immunotherapy in patients with advanced
cancer with rIL-2 was first explored by Rosenberg et al.
(1987). The rIL-2 was given intravenously three times a day
as based on previous work using murine tumours (Rosenberg
et al., 1985). The administration in patients of doses of
100,000 units kg-' every 8 h (median cumulative dose
per patient was 1.8 x 106 U kg-' or approximately
8.4 x 107 Um2) led to a variety of severe side-effects
(Rosenberg et al., 1987). The life threatening toxicity
appeared to be largely due to a reduction in vascular resis-
tance probably due to increased capillary permeability. The
hypovolaemia also resulted in hypotension which on
occasions led to other problems, e.g. renal failure or myo-
cardial infarction. However, these first studies, demonstrated
tumour regression, particularly in patients with advanced
renal cell carcinoma and malignant melanoma. When rIL-2
was given as a continuous 24 h infusion (3 x 106 Um-2) for
5 days, the side-effects were much less and responses were
again noted in good performance stage patients with
melanoma (West et al., 1987). It could be argued that a
continuous infusion results in a sub-optimal tumour response
due to low peak levels of rIL-2.
In our study using an alternate day regimen of high dose
rIL-2 the cumulative dose delivered per patient of
10.6 x 107 U m-2 in the phase I and 14.0 x 107 U m-2 in the
phase II study was comparable to that in the Rosenberg
series. These cumulative doses were delivered over a median
of three courses whereas in the Rosenberg schedule the
cumulative dose of 8.4 x 107 Um2 was given per patient,
the median number of courses administered being one. The
4 h i.v. dose following the intrasplenic dose was not given on
13 occasions, out of a total of 30 doses omitted. There was
no evidence that the intrasplenic dose was associated with
less toxicity than intravenous doses. We were also able to
demonstrate that natural killer and LAK cell activity was
induced in these patients (Ghosh et al., 1989). The induction
of killer cell activity may have resulted partly from the
intrasplenic approach and in experimental models rIL-2 has
induced both lymphoid proliferation in the spleen and LAK
cell activity (Ettinghausen et al., 1985). We were unable to
demonstrate any relationship between lymphocyte count
(total white and also eosinophil counts, data not presented)
and response or survival despite considerable changes in
these cell counts with treatment. West et al. (1987) noted that
tumour response was associated with a good performance
status, a pre-treatment lymphocyte count above
1,400 cells mm 3 and an rIL-2 induced lymphocytosis of at
least 6,000 cells mm3. It was suggested that a threshold
lymphocytosis of 6,000 cellsmm-3 was associated with res-
ponse and if this count was not obtained alternative treat-
ment should be considered. Our data did not support the
association begtween lymphocytosis (or elevation of the total
white count or eosinophilia) and response.774 N. THATCHER et al.
Althoughwewereunabletoobtainanycomplete responsesin
our patients, the majority of whom had three metastatic sites
involved, it was encouraging that response was seen in visceral
sites. Some patients remain alive with stable disease who before
rIL-2 therapy had progressing melanoma. Certainly, the treat-
mentregimen was notassociatedwithahighfrequency ofmajor
side-effects and was generally well tolerated despite a patient
population withveryadvanceddisease andlimited performance
status. Furthermore, side-effects were few and transient and
hospitalisation wasonlyrequired forthe rIL-2 therapyexceptin
two patients.
Further experimental studies with rIL-2 are indicated as it is
now possible to avoid serious side-effects and treatment can be
given onageneral medical wardwithoutintensivecarefacilities.
LAK cell generations may also be unnecessary and different
schedules of rIL-2 either alone or in combination with other
materials, e.g. flavone acetic acid which is known to act
synergistically with rIL-2 in murine systems, can be considered
(Wiltrout et al., 1988). Other techniques currently being
examined include the expansion of the tumour infiltrating
lymphocyte population with rIL-2 using lymphocytes isolated
from the patient's own tumour. The use ofother cytokines and
biological response modifiers, e.g. interferons or tumour nec-
rosis factor, in combination with rIL-2 may also improve the
antitumour effect.
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